PURAPHARM1498.HKValuation Analysis

As of Oct 16, 2026, PURAPHARM (1498.HK) trades at a negative P/E (-4.67x, due to a recent net loss), P/B of 1.04x, P/S of 0.40x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 36th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 3rd percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 77th percentile within its industry and the 56th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/B percentile sits lower across the market than within its own industry — relatively cheaper next to the market as a whole. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. PURAPHARM operates in the Traditional Chinese Medicine Production sector. Data refreshes weekly and is for reference only, not investment advice.